Healthcare

Request for TOC Request for Sample
BUY NOW

North America Molecular Diagnostics Market – Industry Trends and Forecast to 2028

Healthcare | Published Report | Aug 2021 | North America | 350 Pages | No of Tables: 116 | No of Figures: 23

COVID-19 Impact on Molecular Diagnostics in Healthcare Industry

Report Description

North America Molecular Diagnostics Market, By Products (Reagents & Kits, Instruments and Services & Softwares), Technology (Mass Spectrometry (MS), Capillary Electrophoresis, Next Generation Sequencing (NGS), Chips and Microarray, Polymerase Chain Reaction (PCR)-Based Methods, Cytogenetics, In Situ Hybridization (ISH or FISH), Molecular Imaging and Others), Application (Oncology, Pharmacogenomics, Microbiology, Prenatal Tests, Tissue Typing, Blood Screening, Cardiovascular Diseases, Neurological Diseases, Infectious Diseases and Others), End User (Hospital, Clinical Laboratories and Academics), Country (U.S., Canada and Mexico) Industry Trends and Forecast to 2028.

Get Exclusive Sample Copy of this Report Here

Market Analysis and Insights: North America Molecular Diagnostics Market

The molecular diagnostics market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 5.9% in the forecast period of 2021 to 2028 and is expected to reach USD 17,645.46 million by 2028. Increase in prevalence of infectious diseases and cancer is expected to boost the growth of the molecular diagnostics market.

Molecular diagnosis identifies or diagnoses diseases such as infectious diseases, genetic diseases, cardiovascular diseases, neurological diseases, and others by studying molecules such as DNA, RNA, protein in a tissue or a fluid. Different technologies such as PCR, mass spectrometry, -generation sequencing, cytogenetics, in situ hybridization, molecular imaging and others are used to diagnose different diseases.

Rising demand for molecular diagnostic tools to diagnose COVID-19 is expected to boost the growth of the molecular diagnostics market. High cost of instrumentation is expected to act as a major restraint for the growth of the molecular diagnostics market. Rising geriatric population is expected to act as an opportunity for the growth of the molecular diagnostics market. High competition among market players is expected to act as challenge for the growth of the molecular diagnostics market.

The molecular diagnostics market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the molecular diagnostics market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Get Exclusive Sample Copy of this Report Here

Molecular Diagnostics Market Scope and Market Size

The molecular diagnostics market is segmented based on the products, technology, application and end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of products, the molecular diagnostics market is segmented into reagents & kits, instruments and services & softwares. In 2021, the instruments segment is expected to dominate the molecular diagnostics market due to the rise in demand for advanced technology to diagnose diseases such as infectious diseases, cancer and others.
  • On the basis of technology, the molecular diagnostics market is segmented into mass spectrometry (MS), capillary electrophoresis, next generation sequencing (NGS), chips and microarray, polymerase chain reaction (PCR)-based methods, cytogenetics, in situ hybridization (ISH or FISH), molecular imaging and others. In 2021, the polymerase chain reaction (PCR)-based methods segment is expected to dominate the molecular diagnostics market due to increased demand for PCR kits to diagnose COVID-19 and curb the pandemic.
  • On the basis of application, the molecular diagnostics market is segmented into oncology, pharmacogenomics, microbiology, prenatal tests, tissue typing, blood screening, cardiovascular diseases, neurological diseases, infectious diseases and others. In 2021, the infectious diseases segment is expected to dominate the molecular diagnostics market due to the rise in infectious diseases such as flu, COVID-19, AIDS and others and the increased demand for highly efficient molecular diagnostics technology.
  • On the basis of end user, the molecular diagnostics market is segmented into hospital, clinical laboratories and academics. In 2021, the clinical laboratories segment is expected to dominate the molecular diagnostics market due to the rising number of patients with various illnesses and the growing need for diagnostics instruments.

North America Molecular Diagnostics Market Country Level Analysis

North America molecular diagnostics market is analyzed and market size information is provided by the country, products, technology, application and end user as referenced above.

The countries covered in the North America molecular diagnostics market report are the U.S., Canada and Mexico.

The products segment in Canada region is expected to grow with the highest growth rate in the forecast period of 2021 to 2028, because of increase in demand for diagnosis instrument to diagnose COVID-19 patients and other cardiovascular diseases, infectious diseases and others. The products segment in the U.S. is dominating the North America molecular diagnostics market owing to increased healthcare expenditure. Mexico is leading the growth of the North America molecular diagnostics market for risk segment is dominating in this country due to increasing demand for point-of-care testing and precision medicine.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Growing Strategic Activities by Major Market Players to enhance the Awareness for Molecular Diagnostics is Boosting the Molecular Diagnostics Market Growth 

The molecular diagnostics market also provides you with detailed market analysis for every country growth in molecular diagnostics market. Additionally, it provides the detail information regarding the molecular diagnostics market players’ strategy and their geographical presence. The data is available for historic period 2010 to 2019.

Competitive Landscape and Molecular Diagnostics Market Share Analysis

The molecular diagnostics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to North America molecular diagnostics market.

The major companies which are dealing in the North America molecular diagnostics market report are Abbott, Siemens Healthcare GmbH, Thermo Fisher Scientific Inc., BD, bioMérieux SA, Cepheid, Hologic, Inc., Myriad Genetics, Inc., QIAGEN, Agilent Technologies, Inc., Quidel Corporation, Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., Illumina, Inc., IMMUCOR, Luminex Corporation, Meridian Bioscience, F Hoffmann-La Roche Ltd and GenMark Diagnostics, Inc. among other domestic players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many contract, agreement and launches are also initiated by the companies’ worldwide which are also accelerating the molecular diagnostics market.

For instance,

  • In June 2021, Thermo Fisher Scientific Inc. launched a new product named Attune CytPix, a fluorescent flow cytometer that offers enhanced imaging and acoustic focusing with a high-speed camera.

Collaboration, product launch, business expansion, award and recognition, joint ventures and other strategies by the market players is enhancing the company footprints in the molecular diagnostics market which also provides the benefit for organization’s profit growth.


SKU-

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.7 MULTIVARIATE MODELLING

2.8 PRODUCT LIFELINE CURVE

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PRODUCT AND BRAND ANALYSIS: NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET

4.2 ROLE OF ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET

5 MARKET OVERVIEW

5.1 DRIVERS

5.1.1 RISING DEMAND FOR MOLECULAR DIAGNOSTIC TOOLS TO DIAGNOSE COVID-19

5.1.2 INCREASING PREVALENCE OF INFECTIOUS DISEASES AND CANCER

5.1.3 RISING FUNDING FOR MOLECULAR DIAGNOSIS PRODUCTS

5.1.4 RISING DEMAND FOR POINT-OF-CARE (POC) TESTING

5.1.5 DEVELOPMENT OF COMPANION DIAGNOSTIC ASSAY AND PERSONALIZED MEDICINES

5.2 RESTRAINTS

5.2.1 HIGH COST OF INSTRUMENTATIONS

5.2.2 STRINGENT LEGAL AND REGULATORY STANDARDS ARE EXPECTED TO HAMPER THE MARKET GROWTH

5.2.3 DELAY IN APPROVAL OF EXPERIMENTAL TEST FOR MOLECULAR DIAGNOSIS

5.3 OPPORTUNITIES

5.3.1 RISING GERIATRIC POPULATION

5.3.2 INCREASING ADOPTION OF ANALYSER SOFTWARE FOR MOLECULAR DIAGNOSIS

5.3.3 RISING AWARENESS REGARDING RAPID TECHNOLOGICAL ADVANCEMENTS

5.3.4 RISING HEALTHCARE EXPENDITURE IN DEVELOPING REGION

1.4 CHALLENGES

5.3.5 HIGH COMPETITION AMONG MARKET PLAYERS

5.3.6 DISTURBED SUPPLY CHAIN DUE TO COVID-19

6 IMPACT OF COVID-19 ON THE NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET

6.1 ANALYSIS ON IMPACT OF COVID-19 ON THE NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET

6.2 AFTERMATH OF COVID-19 AND GOVERNMENT INITIATIVES FOR GROWTH OF THE MOLECULAR DIAGNOSTICS MARKET

6.3 IMPACT ON DEMAND

6.4 IMPACT ON SUPPLY CHAIN

6.5 IMPACT ON PRICE

6.6 STRATEGIC INITIATIVES BY MANUFACTURERS

6.7 THE RISING COVID-19 CASES IS LEADING THE MOLECULAR DIAGNOSTICS MARKET

6.8 CONCLUSION

7 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT

7.1 OVERVIEW

7.2 INSTRUMENTS

7.2.1 FULLY AUTOMATED INSTRUMENTS

7.2.2 SEMI-AUTOMATED INSTRUMENTS

7.3 REAGENTS AND KITS

7.4 SERVICES AND SOFTWARES

8 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY

8.1 OVERVIEW

8.2 POLYMERASE CHAIN REACTION (PCR)-BASED METHODS

8.2.1 REAL-TIME PCR

8.2.2 DIGITAL PCR

8.2.3 REVERSE TRANSCRIPTASE PCR

8.2.4 QUANTITATIVE FLUORESCENT PCR

8.2.5 DIRECT LINEAR ANALYSIS

8.2.6 COLD PCR

8.3 NEXT GENERATION SEQUENCING (NGS)

8.4 CYTOGENETICS

8.5 CAPILLARY ELECTROPHORESIS

8.6 IN SITU HYBRIDIZATION (ISH OR FISH)

8.7 MOLECULAR IMAGING

8.7.1 OPTICAL IMAGING

8.7.2 FDG-PET

8.8 MASS SPECTROMETRY (MS)

8.9 CHIPS AND MICROARRAY

8.1 OTHERS

9 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION

9.1 OVERVIEW

9.2 INFECTIOUS DISEASES

9.2.1 POLYMERASE CHAIN REACTION (PCR)-BASED METHODS

9.2.2 NEXT GENERATION SEQUENCING (NGS)

9.2.3 CYTOGENETICS

9.2.4 CAPILLARY ELECTROPHORESIS

9.2.5 IN SITU HYBRIDIZATION (ISH OR FISH)

9.2.6 MOLECULAR IMAGING

9.2.7 MASS SPECTROMETRY (MS)

9.2.8 CHIPS AND MICROARRAY

9.2.9 OTHERS

9.3 MICROBIOLOGY

9.3.1 POLYMERASE CHAIN REACTION (PCR)-BASED METHODS

9.3.2 NEXT GENERATION SEQUENCING (NGS)

9.3.3 CYTOGENETICS

9.3.4 CAPILLARY ELECTROPHORESIS

9.3.5 IN SITU HYBRIDIZATION (ISH OR FISH)

9.3.6 MOLECULAR IMAGING

9.3.7 MASS SPECTROMETRY (MS)

9.3.8 CHIPS AND MICROARRAY

9.3.9 OTHERS

9.4 BLOOD SCREENING

9.4.1 POLYMERASE CHAIN REACTION (PCR)-BASED METHODS

9.4.2 NEXT GENERATION SEQUENCING (NGS)

9.4.3 CYTOGENETICS

9.4.4 CAPILLARY ELECTROPHORESIS

9.4.5 IN SITU HYBRIDIZATION (ISH OR FISH)

9.4.6 MOLECULAR IMAGING

9.4.7 MASS SPECTROMETRY (MS)

9.4.8 CHIPS AND MICROARRAY

9.4.9 OTHERS

9.5 ONCOLOGY

9.5.1 ONCOLOGY, BY CANCER TYPE

9.5.1.1 BREAST CANCER

9.5.1.2 COLORECTAL CANCER

9.5.1.3 LUNG CANCER

9.5.1.4 PROSTATE CANCER

9.5.1.5 OTHERS

9.5.2 ONCOLOGY, BY TECHNOLOGY

9.5.2.1 POLYMERASE CHAIN REACTION (PCR)-BASED METHODS

9.5.2.2 NEXT GENERATION SEQUENCING (NGS)

9.5.2.3 CYTOGENETICS

9.5.2.4 CAPILLARY ELECTROPHORESIS

9.5.2.5 IN SITU HYBRIDIZATION (ISH OR FISH)

9.5.2.6 MOLECULAR IMAGING

9.5.2.7 MASS SPECTROMETRY (MS)

9.5.2.8 CHIPS AND MICROARRAY

9.5.2.9 OTHERS

9.6 TISSUE TYPING

9.6.1 POLYMERASE CHAIN REACTION (PCR)-BASED METHODS

9.6.2 NEXT GENERATION SEQUENCING (NGS)

9.6.3 CYTOGENETICS

9.6.4 CAPILLARY ELECTROPHORESIS

9.6.5 IN SITU HYBRIDIZATION (ISH OR FISH)

9.6.6 MOLECULAR IMAGING

9.6.7 MASS SPECTROMETRY (MS)

9.6.8 CHIPS AND MICROARRAY

9.6.9 OTHERS

9.7 PHARMACOGENOMICS

9.7.1 POLYMERASE CHAIN REACTION (PCR)-BASED METHODS

9.7.2 NEXT GENERATION SEQUENCING (NGS)

9.7.3 CYTOGENETICS

9.7.4 CAPILLARY ELECTROPHORESIS

9.7.5 IN SITU HYBRIDIZATION (ISH OR FISH)

9.7.6 MOLECULAR IMAGING

9.7.7 MASS SPECTROMETRY (MS)

9.7.8 CHIPS AND MICROARRAY

9.7.9 OTHERS

9.8 PRENATAL TESTS

9.8.1 POLYMERASE CHAIN REACTION (PCR)-BASED METHODS

9.8.2 NEXT GENERATION SEQUENCING (NGS)

9.8.3 CYTOGENETICS

9.8.4 CAPILLARY ELECTROPHORESIS

9.8.5 IN SITU HYBRIDIZATION (ISH OR FISH)

9.8.6 MOLECULAR IMAGING

9.8.7 MASS SPECTROMETRY (MS)

9.8.8 CHIPS AND MICROARRAY

9.8.9 OTHERS

9.9 NEUROLOGICAL DISEASES

9.9.1 POLYMERASE CHAIN REACTION (PCR)-BASED METHODS

9.9.2 NEXT GENERATION SEQUENCING (NGS)

9.9.3 CYTOGENETICS

9.9.4 CAPILLARY ELECTROPHORESIS

9.9.5 IN SITU HYBRIDIZATION (ISH OR FISH)

9.9.6 MOLECULAR IMAGING

9.9.7 MASS SPECTROMETRY (MS)

9.9.8 CHIPS AND MICROARRAY

9.9.9 OTHERS

9.1 CARDIOVASCULAR DISEASES

9.10.1 POLYMERASE CHAIN REACTION (PCR)-BASED METHODS

9.10.2 NEXT GENERATION SEQUENCING (NGS)

9.10.3 CYTOGENETICS

9.10.4 CAPILLARY ELECTROPHORESIS

9.10.5 IN SITU HYBRIDIZATION (ISH OR FISH)

9.10.6 MOLECULAR IMAGING

9.10.7 MASS SPECTROMETRY (MS)

9.10.8 CHIPS AND MICROARRAY

9.10.9 OTHERS

9.11 OTHERS

9.11.1 POLYMERASE CHAIN REACTION (PCR)-BASED METHODS

9.11.2 NEXT GENERATION SEQUENCING (NGS)

9.11.3 CYTOGENETICS

9.11.4 CAPILLARY ELECTROPHORESIS

9.11.5 IN SITU HYBRIDIZATION (ISH OR FISH)

9.11.6 MOLECULAR IMAGING

9.11.7 MASS SPECTROMETRY (MS)

9.11.8 CHIPS AND MICROARRAY

9.11.9 OTHERS

10 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET, BY END USER

10.1 OVERVIEW

10.2 CLINICAL LABORATORIES

10.3 HOSPITAL

10.4 ACADEMICS

11 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET, BY REGION

11.1 NORTH AMERICA

11.1.1 U.S.

11.1.2 CANADA

11.1.3 MEXICO

12 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET: COMPANY LANDSCAPE

12.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

13 SWOT

14 COMPANY PROFILES

14.1 ABBOTT LABORATORIES

14.1.1 COMPANY SNAPSHOT

14.1.2 REVENUE ANALYSIS

14.1.3 COMPANY SHARE ANALYSIS

14.1.4 PRODUCT PORTFOLIO

14.1.5 RECENT DEVELOPMENTS

14.2 F. HOFFMANN-LA ROCHE LTD

14.2.1 COMPANY SNAPSHOT

14.2.2 REVENUE ANALYSIS

14.2.3 COMPANY SHARE ANALYSIS

14.2.4 PRODUCT PORTFOLIO

14.2.5 RECENT DEVELOPMENTS

14.3 ILLUMINA, INC.

14.3.1 COMPANY SNAPSHOT

14.3.2 REVENUE ANALYSIS

14.3.3 COMPANY SHARE ANALYSIS

14.3.4 PRODUCT PORTFOLIO

14.3.5 RECENT DEVELOPMENTS

14.4 HOLOGIC, INC.

14.4.1 COMPANY SNAPSHOT

14.4.2 REVENUE ANALYSIS

14.4.3 COMPANY SHARE ANALYSIS

14.4.4 PRODUCT PORTFOLIO

14.4.5 RECENT DEVELOPMENTS

14.5 BIOMÉRIEUX SA

14.5.1 COMPANY SNAPSHOT

14.5.2 COMPANY SHARE ANALYSIS

14.5.3 REVENUE ANALYSIS

14.5.4 PRODUCT PORTFOLIO

14.5.5 RECENT DEVELOPMENT

14.6 AGILENT TECHNOLOGIES, INC.

14.6.1 COMPANY SNAPSHOT

14.6.2 REVENUE ANALYSIS

14.6.3 PRODUCT PORTFOLIO

14.6.4 RECENT DEVELOPMENTS

14.7 BD

14.7.1 COMPANY SNAPSHOT

14.7.2 REVENUE ANALYSIS

14.7.3 PRODUCT PORTFOLIO

14.7.4 RECENT DEVELOPMENTS

14.8 BECKMAN COULTER, INC.

14.8.1 COMPANY SNAPSHOT

14.8.2 PRODUCT PORTFOLIO

14.8.3 RECENT DEVELOPMENTS

14.9 BIO-RAD LABORATORIES, INC.

14.9.1 COMPANY SNAPSHOT

14.9.2 REVENUE ANALYSIS

14.9.3 PRODUCT PORTFOLIO

14.9.4 RECENT DEVELOPMENTS

14.1 CEPHEID

14.10.1 COMPANY SNAPSHOT

14.10.2 PRODUCT PORTFOLIO

14.10.3 RECENT DEVELOPMENTS

14.11 GENMARK DIAGNOSTICS, INC.

14.11.1 COMPANY SNAPSHOT

14.11.2 PRODUCT PORTFOLIO

14.11.3 RECENT DEVELOPMENT

14.12 IMMUCOR

14.12.1 COMPANY SNAPSHOT

14.12.2 PRODUCT PORTFOLIO

14.12.3 RECENT DEVELOPMENT

14.13 LIFE TECHNOLOGIES

14.13.1 COMPANY SNAPSHOT

14.13.2 PRODUCT PORTFOLIO

14.13.3 RECENT DEVELOPMENT

14.14 LUMINEX CORPORATION

14.14.1 COMPANY SNAPSHOT

14.14.2 REVENUE ANALYSIS

14.14.3 PRODUCT PORTFOLIO

14.14.4 RECENT DEVELOPMENT

14.15 MERRIDIAN BIOSCIENCE

14.15.1 COMPANY SNAPSHOT

14.15.2 REVENUE ANALYSIS

14.15.3 PRODUCT PORTFOLIO

14.15.4 RECENT DEVELOPMENTS

14.16 MYRIAD GENETICS, INC.

14.16.1 COMPANY SNAPSHOT

14.16.2 REVENUE ANALYSIS

14.16.3 PRODUCT PORTFOLIO

14.16.4 RECENT DEVELOPMENTS

14.17 QIAGEN

14.17.1 COMPANY SNAPSHOT

14.17.2 REVENUE ANALYSIS

14.17.3 PRODUCT PORTFOLIO

14.17.4 RECENT DEVELOPMENTS

14.18 QUIDEL CORPORATION

14.18.1 COMPANY SNAPSHOT

14.18.2 REVENUE ANALYSIS

14.18.3 PRODUCT PORTFOLIO

14.18.4 RECENT DEVELOPMENT

14.19 SIEMENS HEALTHCARE GMBH

14.19.1 COMPANY SNAPSHOT

14.19.2 REVENUE ANALYSIS

14.19.3 PRODUCT PORTFOLIO

14.19.4 RECENT DEVELOPMENTS

14.2 THERMO FISHER SCIENTIFIC INC.

14.20.1 COMPANY SNAPSHOT

14.20.2 REVENUE ANALYSIS

14.20.3 PRODUCT PORTFOLIO

14.20.4 RECENT DEVELOPMENTS

15 QUESTIONNAIRE

16 RELATED REPORTS

List of Table

LIST OF TABLES 

TABLE 1 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 2 NORTH AMERICA INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 3 NORTH AMERICA INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 4 NORTH AMERICA REAGENTS AND KITS IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 5 NORTH AMERICA SERVICES AND SOFTWARES IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 6 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 7 NORTH AMERICA POLYMERASE CHAIN REACTION (PCR)-BASED METHODS IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 8 NORTH AMERICA POLYMERASE CHAIN REACTION (PCR)-BASED METHODS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 9 NORTH AMERICA NEXT GENERATION SEQUENCING (NGS) IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 10 NORTH AMERICA CYTOGENETICS IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 11 NORTH AMERICA CAPILLARY ELECTROPHORESIS IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 12 NORTH AMERICA INS SITU HYBRIDIZATION (ISH OR FISH) IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 13 NORTH AMERICA MOLECULAR IMAGING IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 14 NORTH AMERICA MOLECULAR IMAGING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 15 NORTH AMERICA MASS SPECTROMETRY (MS) IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 16 NORTH AMERICA CHIPS AND MICROARRAY IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 17 NORTH AMERICA OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 18 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 19 NORTH AMERICA INFECTIOUS DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 20 NORTH AMERICA INFECTIOUS DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 21 NORTH AMERICA MICROBIOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 22 NORTH AMERICA MICROBIOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 23 NORTH AMERICA BLOOD SCREENING IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 24 NORTH AMERICA BLOOD SCREENING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 25 NORTH AMERICA ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 26 NORTH AMERICA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)

TABLE 27 NORTH AMERICA ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 28 NORTH AMERICA TISSUE TYPING IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 29 NORTH AMERICA TISSUE TYPING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 30 NORTH AMERICA PHARMACOGENOMICS IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 31 NORTH AMERICA PHARMACOGENOMICS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 32 NORTH AMERICA PRENATAL TESTS IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 33 NORTH AMERICA PRENATAL TESTS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 34 NORTH AMERICA NEUROLOGICAL DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 35 NORTH AMERICA NEUROLOGICAL DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 36 NORTH AMERICA CARDIOVASCULAR DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 37 NORTH AMERICA CARDIOVASCULAR DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 38 NORTH AMERICA OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 39 NORTH AMERICA OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 40 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 41 NORTH AMERICA CLINICAL LABORATORIES IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 42 NORTH AMERICA HOSPITAL IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 43 NORTH AMERICA ACADEMICS IN MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 44 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 45 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 46 NORTH AMERICA INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 47 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 48 NORTH AMERICA POLYMERASE CHAIN REACTION (PCR)-BASED METHODS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 49 NORTH AMERICA MOLECULAR IMAGING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 50 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 51 NORTH AMERICA ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)

TABLE 52 NORTH AMERICA ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 53 NORTH AMERICA PHARMACOGENOMICS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 54 NORTH AMERICA MICROBIOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 55 NORTH AMERICA PRENATAL TESTS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 56 NORTH AMERICA TISSUE TYPING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 57 NORTH AMERICA BLOOD SCREENING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 58 NORTH AMERICA CARDIOVASCULAR DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 59 NORTH AMERICA NEUROLOGICAL DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 60 NORTH AMERICA INFECTIOUS DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 61 NORTH AMERICA OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 62 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 63 U.S. MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 64 U.S. INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 65 U.S. MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 66 U.S. POLYMERASE CHAIN REACTION (PCR)-BASED METHODS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 67 U.S. MOLECULAR IMAGING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 68 U.S. MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 69 U.S. ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)

TABLE 70 U.S. ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 71 U.S. PHARMACOGENOMICS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 72 U.S. MICROBIOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 73 U.S. PRENATAL TESTS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 74 U.S. TISSUE TYPING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 75 U.S. BLOOD SCREENING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 76 U.S. CARDIOVASCULAR DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 77 U.S. NEUROLOGICAL DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 78 U.S. INFECTIOUS DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 79 U.S. OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 80 U.S. MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 81 CANADA MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 82 CANADA INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 83 CANADA MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 84 CANADA POLYMERASE CHAIN REACTION (PCR)-BASED METHODS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 85 CANADA MOLECULAR IMAGING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 86 CANADA MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 87 CANADA ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)

TABLE 88 CANADA ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 89 CANADA PHARMACOGENOMICS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 90 CANADA MICROBIOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 91 CANADA PRENATAL TESTS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 92 CANADA TISSUE TYPING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 93 CANADA BLOOD SCREENING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 94 CANADA CARDIOVASCULAR DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 95 CANADA NEUROLOGICAL DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 96 CANADA INFECTIOUS DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 97 CANADA OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 98 CANADA MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 99 MEXICO MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 100 MEXICO INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 101 MEXICO MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 102 MEXICO POLYMERASE CHAIN REACTION (PCR)-BASED METHODS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 103 MEXICO MOLECULAR IMAGING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 104 MEXICO MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 105 MEXICO ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)

TABLE 106 MEXICO ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 107 MEXICO PHARMACOGENOMICS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 108 MEXICO MICROBIOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 109 MEXICO PRENATAL TESTS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 110 MEXICO TISSUE TYPING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 111 MEXICO BLOOD SCREENING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 112 MEXICO CARDIOVASCULAR DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 113 MEXICO NEUROLOGICAL DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 114 MEXICO INFECTIOUS DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 115 MEXICO OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 116 MEXICO MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)

 

List of Figure

LIST OF FIGURES 

FIGURE 1 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET: SEGMENTATION

FIGURE 2 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET: DATA TRIANGULATION

FIGURE 3 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET: DROC ANALYSIS

FIGURE 4 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID

FIGURE 8 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET: DBMR VENDOR SHARE ANALYSIS

FIGURE 9 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET: SEGMENTATION

FIGURE 10 NORTH AMERICA IS EXPECTED TO DOMINATE THE NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET AND GROWING WITH THE HIGHEST SHARE IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 11 THE INCREASING PREVALENCE OF INFECTIOUS DISEASES AND CANCER IS EXPECTED TO DRIVE THE NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 12 INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET IN 2021 & 2028

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET

FIGURE 14 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2020

FIGURE 15 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020

FIGURE 16 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2020

FIGURE 17 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2020

FIGURE 18 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET: SNAPSHOT (2020)

FIGURE 19 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET: BY COUNTRY (2020)

FIGURE 20 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET: BY COUNTRY (2021 & 2028)

FIGURE 21 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET: BY COUNTRY (2020 & 2028)

FIGURE 22 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET: BY PRODUCT (2021 & 2028)

FIGURE 23 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET: COMPANY SHARE 2020 (%)

 

View Infographics

LIST OF FIGURES 

FIGURE 1 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET: SEGMENTATION

FIGURE 2 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET: DATA TRIANGULATION

FIGURE 3 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET: DROC ANALYSIS

FIGURE 4 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID

FIGURE 8 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET: DBMR VENDOR SHARE ANALYSIS

FIGURE 9 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET: SEGMENTATION

FIGURE 10 NORTH AMERICA IS EXPECTED TO DOMINATE THE NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET AND GROWING WITH THE HIGHEST SHARE IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 11 THE INCREASING PREVALENCE OF INFECTIOUS DISEASES AND CANCER IS EXPECTED TO DRIVE THE NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 12 INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET IN 2021 & 2028

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET

FIGURE 14 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2020

FIGURE 15 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020

FIGURE 16 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2020

FIGURE 17 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2020

FIGURE 18 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET: SNAPSHOT (2020)

FIGURE 19 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET: BY COUNTRY (2020)

FIGURE 20 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET: BY COUNTRY (2021 & 2028)

FIGURE 21 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET: BY COUNTRY (2020 & 2028)

FIGURE 22 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET: BY PRODUCT (2021 & 2028)

FIGURE 23 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET: COMPANY SHARE 2020 (%)

 

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19